Earnings Week Ahead: PLTR, AMD, Pfizer, Disney, and Shopify Report Aug. 3-7, 2026

The week of August 3 to 7, 2026, could become one of the most consequential stretches of earnings season, with major companies reporting across AI, semiconductors, healthcare, consumer products, energy, travel, and software. Palantir and AMD will offer fresh evidence on AI demand and infrastructure spending, while Pfizer, Disney, and Shopify will provide a broader read on drug development, entertainment, retail, and consumer activity.

For investors tracking the market through Patriot Market Research, the key questions extend beyond whether companies beat quarterly estimates. Results from Palantir, AMD, Pfizer, Disney, Shopify, and other widely followed names could reveal whether strong growth is holding up, how tariffs and costs are affecting margins, and whether businesses are increasing capital spending. The week may also bring important updates on advertising, healthcare demand, travel bookings, energy prices, and software monetization.

This preview examines the biggest reports, consensus expectations, business questions, and trends that could influence stock prices. Earnings dates and release times can change, so confirm each detail through company filings or a trusted earnings calendar before trading.

Key Takeaways

• Palantir and AMD lead the week, with investors focused on AI demand, revenue growth, margins, and infrastructure spending.

• Pfizer faces a major patent cliff while building oncology and obesity-drug pipelines to support future growth.

• Disney's results will test streaming profitability, park attendance, advertising, and Josh D'Amaro's early leadership priorities.

• Shopify must show that strong merchant growth and record GMV can offset higher AI costs and lower-margin payment revenue.

• Patriot Market Research rates PLTR, PFE, DIS, and SHOP at Hold, while its Quant Rating remains Strong Buy on AMD.

Earnings Week Ahead: Key Companies Reporting August 3 to 7, 2026

The August 3 to 7 earnings calendar includes hundreds of reports, but a handful of companies will set the tone for AI spending, healthcare demand, travel, streaming, digital commerce, and consumer costs. Release dates and timing can change, so investors should verify details before trading.

Monday brings an early look at AI, drugs, travel, and consumer demand

Palantir Technologies is expected to report after Monday's close, making it the week's first major AI test. Its prior quarter delivered 85% year-over-year revenue growth, a 60% adjusted operating margin, and U.S. commercial revenue growth above 100%. Management guided second-quarter revenue near $1.8 billion. Investors now need evidence that demand for AIP, Foundry, and government deployments can support another strong outlook without weakening margins.

Vertex Pharmaceuticals could offer fresh detail on its pipeline beyond cystic fibrosis, including progress in pain, kidney disease, and other specialty treatments. Marriott International will provide a read on hotel bookings, pricing power, international travel, and corporate demand. Tyson Foods faces a different test: volumes, protein prices, labor expenses, and whether consumers are trading down.

Clorox's report should show whether pricing still offsets softer household demand and higher input costs. Meanwhile, ON Semiconductor remains a useful indicator for the chip cycle, especially automotive and industrial demand, inventory levels, and factory utilization.

Tuesday centers on AMD's AI challenge and Pfizer's patent cliff

AMD reports after Tuesday's close, with investors focused on whether it can convert AI demand into sustained data-center growth. The company produced $10.25 billion in prior-quarter revenue and guided toward roughly $11.2 billionfor Q2, with non-GAAP gross margin near 56%.

The MI400 accelerator family and Helios rack platform have strengthened AMD's challenge to NVIDIA. The earnings call must clarify hyperscaler orders, product supply, rack-scale deployment, and the margin impact of accelerating AI infrastructure investment. Strong demand matters, but so does AMD's ability to deliver systems at profitable prices.

Pfizer is expected before Tuesday's open. Its prior revenue reached $14.45 billion, while full-year guidance remains $59.5 billion to $62.5 billion. The company faces about $17 billion of revenue at risk from patent expirations through 2030, making product mix a central issue.

Oncology growth, including medicines from Seagen, and progress in the obesity drug pipeline could support Pfizer's longer-term case. However, declining COVID sales, pricing pressure, tariffs, and patent losses continue to weigh on the near-term outlook.

Wednesday tests streaming, digital commerce, and advertising growth

Disney's fiscal third-quarter report arrives before Wednesday's opening bell, during Josh D'Amaro's first full quarter as CEO. Prior revenue was $25.17 billion, supported by streaming and affiliate revenue growth, the Fubo integration, and continued demand at parks.

Investors will watch attendance, per-guest spending, streaming profitability, share repurchases, and the early direction of Hulu and Fubo. Higher sports programming costs could pressure margins, especially if Sports operating income falls as projected.

Shopify also reports Wednesday, with prior revenue of $3.17 billion and quarterly GMV above $100 billion. Management expects revenue growth in the high 20% range. The key question is whether merchant expansion and payments growth can outweigh higher AI infrastructure costs and the lower margins associated with Merchant Solutions.

The DoorDash commerce integration expands Shopify's sales channels, but investors will judge both companies on growth quality and future margins. Eli Lilly, Uber, Etsy, MercadoLibre, Unity, eBay, and Western Digital add further signals on healthcare, travel, online retail, software, and storage demand.

Thursday and Friday shift attention to healthcare, media, travel, and cannabis

Viatris reports before Thursday's open. The company posted prior revenue of $3.52 billion and reaffirmed full-year revenue guidance of $14.45 billion to $14.95 billion, with adjusted EBITDA guidance of $4.15 billion to $4.45 billion.

Investors will assess branded medicine demand, margin expansion, pipeline growth, and progress under the Phase 2 transformation plan. Recent regulatory progress, including octreotide approval, could support the company's broader portfolio strategy.

Friday's premarket report from Canopy Growth will focus on whether losses continue to narrow. Stronger Canadian medical cannabis revenue, international growth, German expansion, and tighter cost control are essential to its path toward sustainable profitability.

Roku, Airbnb, The Trade Desk, Cloudflare, Datadog, DraftKings, Warner Bros. Discovery, and Lyft will also report across Thursday and Friday. Their results will add detail on advertising, travel, streaming, software budgets, and consumer spending.

The biggest earnings themes for investors to track

This earnings week is less about isolated EPS beats and more about cross-company evidence. Investors should compare forward guidance, margins, cash flow, and demand across sectors. A strong headline result can still disappoint if management lowers its outlook or spends heavily to protect growth.

AI spending faces its next major reality check

The AI investment chain runs from customers to infrastructure and software. Palantir will show whether governments and businesses are expanding real deployments, while AMD and Arista Networks provide clues about accelerator and networking demand. ON Semiconductor, Sandisk, and Western Digital add evidence on power systems, memory, and storage needed for data centers.

Cloud providers remain the key source of infrastructure spending, but inference growth could broaden demand beyond training large models. AMD's MI400 products and Helios rack platform have raised expectations, while Palantir's reported 85% first-quarter revenue growth and 104% U.S. commercial growth set a high bar. The question is whether new contracts convert into durable revenue and cash flow.

Software companies must prove that AI creates revenue, rather than simply increasing costs. AppLovin, Cloudflare, and Datadog can show whether customers are paying for AI-powered advertising, security, and cloud monitoring. The Trade Desk offers another test through advertising budgets and campaign performance.

Investors should separate signed contracts, usage growth, and rising revenue from broad claims about future AI demand.

High valuations leave little room for vague guidance. Strong adoption may not support a stock if margins fall, capital spending rises, or management gives conservative targets. Patriot Market Research rates Palantir at Hold despite its growth, while its Quant Rating remains Strong Buy on AMD. That contrast shows why valuation and execution matter as much as the theme.

Healthcare results will show where growth can replace lost revenue

Pfizer's roughly $17 billion in revenue exposed to patent expirations through 2030 makes product mix more important than one quarterly beat. Falling COVID sales add pressure, so investors need updates on oncology, including Seagen medicines, and the oral obesity program. Trial starts, regulatory decisions, pricing pressure, and long-term guidance may matter more than current sales.

Eli Lilly and Novo Nordisk face questions about obesity-drug demand, supply, competition, and pricing. Merck must sustain oncology growth, while Gilead Sciences and Amgen offer different tests around pipeline progress and specialty-drug demand. Vertex Pharmaceuticals remains focused on expanding beyond cystic fibrosis.

CVS Health will provide a read on medical utilization, reimbursement, and pharmacy economics. Viatris needs branded growth, pipeline execution, and margin expansion, while falling COVID revenue affects the sector's comparisons. Healthcare investors should focus on the products that can replace lost revenue over several years, not only the quarter that just ended.

Consumer and travel reports reveal whether spending is holding up

Disney's attendance, streaming subscriptions, advertising, and per-guest spending will show whether entertainment demand remains firm. Marriott and Booking Holdings offer complementary evidence through room rates, bookings, and international travel. McDonald's can reveal restaurant traffic and value-seeking behavior, while Uber adds data on rides and delivery demand.

Spotify's subscription growth and advertising trends matter for digital media. Kraft Heinz and Tyson Foods can show whether shoppers are choosing cheaper products or reducing volumes. Etsy and MercadoLibre provide a sharper test of marketplace activity, advertising, payment growth, and customer trade-down behavior.

Strong spending would support earnings across travel and entertainment. Weaker discretionary demand could pressure bookings, park attendance, restaurant traffic, and online marketplaces even when companies maintain pricing.

Energy and industrial results will reflect prices, demand, and capital plans

BP, ConocoPhillips, Occidental Petroleum, Devon Energy, and EOG Resources will be judged on oil and gas prices, production, cash flow, dividends, and buybacks. Phillips 66 and Marathon Petroleum add refining-margin data, while Cheniere Energy provides clues about LNG volumes and global demand.

Duke Energy and Vistra should benefit from rising power demand, including data centers, but investors will examine grid investment and capital requirements. Caterpillar, Cummins, Emerson Electric, Nutrien, and Sterling Infrastructure can reveal whether industrial backlogs and infrastructure spending are holding up despite tariffs.

In cyclical industries, revenue growth matters less if it consumes too much capital. Investors should compare free cash flow with capital expenditure, then assess whether dividends and buybacks remain affordable when commodity prices or industrial orders weaken.

What to watch beyond the headline earnings numbers

An earnings release is only the starting point. Investors should read the outlook, cash flow statement, segment results, and conference call before deciding whether a beat changes the investment case. A company can exceed EPS estimates and still fall if its forecast, margins, or customer demand disappoint.

Guidance and revisions may matter more than the quarter just finished

The reported quarter is history. Guidance sets the market's expectations for the next several quarters, so even a strong EPS beat may not help if management lowers its forecast.

AMD offers a clear example. The company guided for second-quarter revenue of about $11.2 billion, plus or minus $300 million, with non-GAAP gross margin near 56%. That outlook implies strong annual growth, but consensus revenue was slightly higher at roughly $11.31 billion. Investors therefore need to compare the actual result and new forecast with both the analyst estimate and AMD's prior promises about hyperscaler demand, AI accelerators, and rack-scale systems.

Pfizer reaffirmed 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted EPS guidance of $2.80 to $3.00. That decision may matter more than a quarterly beat because the company still faces about $17 billion of revenue exposure to patent expirations through 2030. Readers should ask whether oncology launches, obesity-drug development, and cost controls can support those targets as COVID revenue declines.

Disney's projected segment operating income also deserves attention. Strength in streaming and Experiences must offset a projected mid-teens decline in Sports operating income from higher programming rights costs. Shopify's high-20% revenue-growth outlook faces a similar test: can merchant growth and payments activity support expectations after higher AI infrastructure spending?

Viatris has reaffirmed full-year revenue of $14.45 billion to $14.95 billion and adjusted EBITDA of $4.15 billion to $4.45 billion. Compare those targets with its Phase 2 efficiency plans, branded-medicine growth, and recent pipeline progress. The key question is whether management has raised its promise, repeated it, or quietly narrowed the path to achieving it.

Margins, cash flow, and spending reveal the quality of growth

Revenue growth can look impressive while profits weaken. Palantir's unusually high adjusted operating margin, recently around 60%, gives investors a demanding benchmark for future execution. Shopify, meanwhile, expects free cash flow margins in the mid-teens while investing more in AI infrastructure and handling a larger mix of lower-margin Merchant Solutions.

AMD's roughly 56% non-GAAP gross-margin target shows why product mix matters. Higher-priced AI systems may lift sales, but supply costs, packaging, and rack deployments can limit the benefit. Viatris offers another angle through its efficiency goals and planned margin expansion.

Adjusted earnings remove items that management considers unusual, while GAAP results include stock-based compensation, restructuring costs, amortization, and other charges. Investors should review both measures rather than treating adjusted EPS as the complete picture. Also check:

• Operating cash flow, to see whether reported profits convert into cash.

• Capital spending, especially where AI infrastructure or manufacturing investment is rising.

• Stock-based compensation, which can reduce shareholder value through dilution.

• Debt maturities, interest expense, buybacks, and whether repurchases are affordable.

A company that grows revenue but consumes more cash each quarter may need to explain why. Buybacks also deserve scrutiny when debt remains high or the stock trades at an expensive valuation.

Management commentary can confirm or weaken the main investment story

The conference call often reveals more than the earnings tables. Listen for changes in AI demand, customer retention, drug launches, travel bookings, sports-rights costs, international expansion, cannabis regulation, commodity prices, and tariffs.

Use four questions while listening:

1. What improved compared with the prior quarter?

2. What worsened, and was the change temporary or structural?

3. Which assumptions changed from management's last forecast?

4. What does management expect during the next quarter and full year?

For Palantir and AMD, signed contracts, deployment timing, repeat usage, and hyperscaler orders matter more than broad statements about AI interest. Shopify investors should seek evidence of merchant retention and profitable growth. Pfizer's call should address Padcev, Adcetris, obesity research, pricing pressure, and patent losses. Disney needs clarity on streaming profitability, park demand, advertising, and sports costs. Canopy Growth must discuss Canadian market share, Germany, international revenue, and its route toward sustainable profitability.

A long record of earnings beats, such as Palantir's and AMD's eight-quarter streaks, doesn't guarantee a positive stock reaction. Patriot Market Research's more cautious Hold ratings on several names reinforce the point: credibility depends on what management delivers against its previous commitments, not only on the number printed at the top of the release.

How Patriot Market Research can help frame the earnings week

Patriot Market Research brings several inputs together before an earnings release: company fundamentals, analyst estimates, market expectations, valuation, and quantitative signals. That wider view helps investors judge whether a reported beat is genuinely positive or already reflected in the stock price.

The research also shows why ratings can disagree. Wall Street holds Buy or Strong Buy consensus views on Palantir, AMD, Disney, Shopify, Pfizer, Viatris, and Canopy Growth. PMR's Quant Rating is more cautious on several of those companies, including PLTR, PFE, DIS, SHOP, VTRS, and CGC, while AMD remains a Strong Buy under the PMR system. Those differences are useful research inputs, not automatic buy or sell signals.

Use earnings history as context, not a promise

A long record of beating estimates can build confidence, but it also raises the bar. When a company repeatedly exceeds consensus, investors often begin to expect another surprise. A result that technically beats estimates may still disappoint if the margin is smaller than usual or management offers a cautious outlook.

Palantir has beaten both EPS and revenue estimates in each of its past eight quarters. AMD has also exceeded revenue estimates in all eight reports, while beating EPS expectations in seven. Those records support the case for strong execution, yet they create demanding expectations around AI demand, data-center orders, product supply, and future margins.

Disney has delivered eight straight quarterly EPS beats, while Shopify has exceeded revenue estimates in each of its past eight reports. Disney's revenue record is less consistent, with six beats over that period, and Shopify has topped EPS expectations in four reports. That distinction matters because investors may place more weight on subscriber trends, GMV, payment mix, free cash flow, and guidance than on EPS alone.

Pfizer has beaten revenue estimates in seven of the past eight quarters and topped EPS expectations in all eight. Viatris has beaten both measures in seven of its past eight reports. Those streaks can support management credibility, but Pfizer still faces patent expirations and declining COVID revenue, while Viatris must show that branded-medicine growth and cost controls can continue.

Canopy Growth has a weaker history. It exceeded revenue estimates in only three of its past eight quarters and beat EPS expectations once. A better-than-expected loss may still matter, especially if Canadian medical cannabis and international sales improve, but one positive quarter won't erase the company's profitability risks.

A beat is only one part of the result. The stock reaction depends on the size of the surprise, the next forecast, and the price investors already paid for growth.

Before trading, compare each release with four reference points:

• The reported EPS and revenue versus consensus.

• The size of the beat or miss compared with the company's recent pattern.

• New guidance, margin expectations, and management commentary.

• The stock's valuation, volatility, and likely reaction to good or bad news.

A high-growth company can beat estimates and still decline if its valuation assumes even stronger results. Conversely, a lower-rated company may rally after a modest beat if expectations were weak. Investors should also review SEC filings, earnings releases, and conference-call transcripts directly. PMR can help frame the evidence, but each reader must match the data with their risk tolerance, time horizon, and investment plan.

A practical plan for following earnings from August 3 to 7

A crowded earnings week is easier to follow when you organize reports around business questions instead of scrolling through headlines. Start with a short watchlist, confirm each release time, record the estimates, and decide which updates could change your long-term view.

Palantir is scheduled to report after Monday's close, while AMD reports after Tuesday's close. Pfizer is due before Tuesday's open, and Disney and Shopify are expected before Wednesday's open. Check company investor-relations pages because release times can change.

Build a watchlist by sector and business question

Group the week into a few themes, then write one question beside each group. This keeps the process focused when dozens of companies report.

• AI and semiconductors: Palantir, AMD, Arista Networks, and ON Semiconductor can answer, Is AI demand broadening beyond a small group of infrastructure buyers? Watch revenue growth, customer deployments, data-center orders, product supply, and margins.

• Healthcare: Pfizer, Eli Lilly, Merck, Vertex, and Viatris raise the question, Can new medicines offset patent losses?Pfizer's roughly $17 billion in revenue at risk through 2030 makes oncology launches, obesity research, and pipeline progress more important than a single quarterly beat.

• Consumer and travel: Disney, Marriott, McDonald's, Uber, Booking Holdings, and Shopify help answer, Is the consumer still resilient? Look at attendance, bookings, transaction volume, merchant activity, pricing, and signs of trade-down behavior.

• Energy and industrials: BP, ConocoPhillips, Caterpillar, Cummins, Duke Energy, and Vistra address, Are commodity and power trends supporting cash flow? Compare production, prices, backlogs, capital spending, and free cash flow.

• Emerging technology: Canopy Growth, Unity, IonQ, Rigetti Computing, Oklo, and Joby Aviation ask, Are speculative businesses moving closer to profitability? Focus on cash use, funding needs, revenue quality, and milestones rather than promotional announcements.

Before each report, save the consensus EPS and revenue estimates, prior guidance, and the company's recent results. AMD's consensus revenue estimate is about $11.31 billion, compared with management's guidance near $11.2 billion, plus or minus $300 million. Options markets imply a post-earnings move near 12%, which warns readers to expect a large price swing.

Compare the market reaction with the actual business update

The first price move is useful, but it isn't the full verdict. A stock can fall after beating estimates when investors expected an even larger surprise, stronger guidance, or faster margin expansion. Conversely, a company can rise after reporting a loss if its forecast improves or cash use slows.

After the release, compare five items:

1. Actual EPS and revenue against consensus.

2. Results against the company's prior guidance.

3. New forecasts, margins, cash flow, and capital spending.

4. Valuation and the expectations already priced into the stock.

5. Options-implied volatility and management's tone on the call.

Palantir and AMD face high expectations after repeated estimate beats, so contract timing and future AI demand may matter more than the headline EPS number. Shopify needs to show that merchant growth and GMV can offset AI infrastructure costs and lower-margin payments. Disney must balance streaming and parks against sports-rights expenses. Canopy Growth may rally after another narrower loss, but investors still need evidence of durable revenue growth and a credible path to profitability.

Avoid emotional trades during after-hours gaps. Let the release, call, and revised thesis settle before acting. Patriot Market Research can help frame the numbers, but the key decision is simple: did the report strengthen, weaken, or leave your long-term investment case unchanged?

Conclusion

August 3 to 7, 2026, brings an unusually broad earnings test, with AI demand, healthcare pipelines, consumer resilience, digital commerce, energy markets, and capital spending all in focus. Palantir and AMD will show whether AI adoption is translating into durable revenue and profitable infrastructure growth. Pfizer and Viatris must demonstrate that pipeline progress and branded medicines can offset patent pressure, while Disney and Shopify will provide important evidence on entertainment demand, merchant activity, streaming, and consumer spending.

Energy and industrial reports will add context on commodity prices, power demand, infrastructure investment, and capital allocation. Canopy Growth faces a different challenge, as investors look for stronger international sales, improved Canadian medical cannabis performance, and continued progress toward profitability.

The strongest takeaway is to look beyond headline EPS. Guidance, margins, cash flow, and long-term business trends will matter more than a single quarterly beat, especially for companies with high expectations. Confirm report dates and times through company investor-relations pages, including Palantir's Aug. 3 release and AMD's Aug. 4 report, then complete independent research before making investment decisions.